Back to Search Start Over

Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years.

Authors :
D'Angelo NA
Noronha MA
Câmara MCC
Kurnik IS
Feng C
Araujo VHS
Santos JHPM
Feitosa V
Molino JVD
Rangel-Yagui CO
Chorilli M
Ho EA
Lopes AM
Source :
Biomaterials advances [Biomater Adv] 2022 Feb; Vol. 133, pp. 112623. Date of Electronic Publication: 2021 Dec 23.
Publication Year :
2022

Abstract

Doxorubicin (DOX) is a natural antibiotic with antineoplastic activity. It has been used for over 40 years and remains one of the most used drugs in chemotherapy for a variety of cancers. However, cardiotoxicity limits its use for long periods. To overcome this limitation, encapsulation in smart drug delivery systems (DDS) brings advantages in comparison with free drug administration (i.e., conventional anticancer drug therapy). In this review, we present the most relevant nanostructures used for DOX encapsulation over the last 10 years, such as liposomes, micelles and polymeric vesicles (i.e., polymersomes), micro/nanoemulsions, different types of polymeric nanoparticles and hydrogel nanoparticles, as well as novel approaches for DOX encapsulation. The studies highlighted here show these nanoformulations achieved higher solubility, improved tumor cytotoxicity, prolonged DOX release, as well as reduced side effects, among other interesting advantages.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2021 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
2772-9508
Volume :
133
Database :
MEDLINE
Journal :
Biomaterials advances
Publication Type :
Academic Journal
Accession number :
35525766
Full Text :
https://doi.org/10.1016/j.msec.2021.112623